Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

This study has been completed.
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred Identifier:
First received: September 13, 2005
Last updated: January 19, 2012
Last verified: January 2012
The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

HIV Infection
CMV Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

Resource links provided by NLM:

Further study details as provided by The Alfred:

Biospecimen Retention:   Samples With DNA
Plasma, and DNA

Enrollment: 20
Study Start Date: December 2004
Study Completion Date: December 2009

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV infected patients with past CMV infection initiating antiretroviral therapy

Inclusion Criteria:

  1. HIV positive with history of documented HCV infection
  2. Over 18 years old
  3. HIV positive
  4. Antiretroviral naive, starting on antiretroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00168259

Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
Principal Investigator: Sharon Lewin, Professor The Alfred
  More Information

Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred Identifier: NCT00168259     History of Changes
Other Study ID Numbers: 185/04
Study First Received: September 13, 2005
Last Updated: January 19, 2012

Keywords provided by The Alfred:
Treatment Naive

Additional relevant MeSH terms:
Communicable Diseases
HIV Infections
Cytomegalovirus Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Herpesviridae Infections
DNA Virus Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on May 25, 2017